Candel Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Candel Therapeutics
CADL Stock  USD 5.84  0.09  1.52%   
Candel Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Candel Therapeutics' valuation are provided below:
Gross Profit
-23.1 M
Market Capitalization
320.6 M
Enterprise Value Revenue
821.9774
Revenue
31 K
Earnings Share
(0.56)
There are over one hundred nineteen available fundamental signals for Candel Therapeutics, which can be analyzed over time and compared to other ratios. We recommend to validate Candel Therapeutics' prevailing fundamental drivers against the all of the trends between 2010 and 2026. Market Cap is expected to rise to about 259.8 M this year. Enterprise Value is expected to rise to about 175.5 M this year
Check Candel Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Candel Therapeutics' main balance sheet or income statement drivers, such as Interest Income of 1.2 M, Depreciation And Amortization of 1.2 M or Interest Expense of 2.5 M, as well as many indicators such as Price To Sales Ratio of 451, Dividend Yield of 0.0 or PTB Ratio of 3.92. Candel financial statements analysis is a perfect complement when working with Candel Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Candel Stock
Check out the analysis of Candel Therapeutics Correlation against competitors.
For more information on how to buy Candel Stock please use our How to buy in Candel Stock guide.

Candel Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets73.3 M122.9 M59.4 M
Slightly volatile
Short and Long Term Debt Total11.2 M15.5 M5.4 M
Slightly volatile
Other Current Liabilities32.4 M30.9 M7 M
Slightly volatile
Total Current Liabilities45.3 M43.2 M10 M
Slightly volatile
Other Liabilities2.2 M2.3 M4 M
Very volatile
Property Plant And Equipment Net3.5 M3.1 M1.8 M
Slightly volatile
Accounts Payable202.6 K213.3 K361.5 K
Pretty Stable
Cash60.7 M118.1 M32.7 M
Slightly volatile
Non Current Assets Total4.1 M3.5 M2.1 M
Slightly volatile
Non Currrent Assets Other369.6 K378.4 K303.4 K
Slightly volatile
Other Assets358.9 K305.9 K288 K
Slightly volatile
Long Term Debt2.8 M3 M2.8 M
Slightly volatile
Cash And Short Term Investments68 M118.1 M56.6 M
Slightly volatile
Common Stock Total Equity189.9 K328.9 K172.9 K
Slightly volatile
Common Stock Shares Outstanding28.5 M36.4 M22.9 M
Slightly volatile
Liabilities And Stockholders Equity73.3 M122.9 M59.4 M
Slightly volatile
Non Current Liabilities Total2.6 M2.7 M38.2 M
Slightly volatile
Other Current Assets1.3 M1.3 M644 K
Slightly volatile
Total Liabilities32.1 M36.5 M46.7 M
Slightly volatile
Property Plant And Equipment Gross4.8 M6.7 M2.4 M
Slightly volatile
Total Current Assets69.3 M119.4 M57.3 M
Slightly volatile
Capital Stock287.3 K539.4 K202.2 K
Slightly volatile
Net Working Capital56.7 M76.2 M49.2 M
Slightly volatile
Common Stock287.3 K539.4 K202.2 K
Slightly volatile
Property Plant Equipment3.4 M6.3 M2.2 M
Slightly volatile
Current Deferred Revenue123.1 K129.6 K2.1 M
Slightly volatile
Deferred Long Term Liabilities537.4 K1 M356.1 K
Slightly volatile
Short and Long Term Debt7.1 M11.4 M3.5 M
Slightly volatile
Short Term Debt12.6 M12 M3 M
Slightly volatile
Long Term Debt Total448 K504 K550.1 K
Slightly volatile
Capital Surpluse115.3 M129.7 M141.6 M
Slightly volatile
Non Current Liabilities Other14.6 M16.4 M17.9 M
Slightly volatile

Candel Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income1.2 M1.2 M1.1 M
Pretty Stable
Depreciation And Amortization1.2 M1.1 M342.1 K
Slightly volatile
Interest Expense2.5 M2.4 M1.2 M
Slightly volatile
Selling General Administrative11 M16.2 M6.4 M
Slightly volatile
Selling And Marketing Expenses768.1 K790 K444.8 K
Slightly volatile
Other Operating Expenses28.3 M38.4 M17.9 M
Slightly volatile
Research Development17.4 M22.2 M11.4 M
Slightly volatile
Cost Of Revenue1.1 M1.1 M5.6 M
Pretty Stable
Total Operating Expenses22.7 M37.2 M12.2 M
Slightly volatile
Reconciled Depreciation1.2 M1.1 M340.4 K
Slightly volatile

Candel Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation6.4 M6.1 M1.9 M
Slightly volatile
Begin Period Cash Flow46.6 M41 M33 M
Slightly volatile
Depreciation626.5 K1.1 M327.6 K
Slightly volatile
Capital Expenditures13.7 K14.4 K394.1 K
Pretty Stable
End Period Cash Flow61 M118.4 M33 M
Slightly volatile
Cash And Cash Equivalents Changes38.2 M43 M46.9 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio451475911
Slightly volatile
Stock Based Compensation To Revenue12.4416.619.234
Slightly volatile
Capex To Depreciation0.01770.01863.7166
Pretty Stable
EV To Sales37.939.89717
Slightly volatile
Payables Turnover4.564.826.3892
Slightly volatile
Sales General And Administrative To Revenue50.8210147.0796
Slightly volatile
Research And Ddevelopement To Revenue82.1215085.3349
Slightly volatile
Capex To Revenue7.629.345.1351
Slightly volatile
Cash Per Share1.872.922.3832
Very volatile
Days Payables Outstanding82.5778.6427.1412
Slightly volatile
Income Quality0.640.440.6797
Pretty Stable
Net Debt To EBITDA2.051.971.1744
Slightly volatile
Current Ratio3.023.1821.6653
Slightly volatile
Capex Per Share6.0E-46.0E-40.0171
Pretty Stable
Revenue Per Share0.00610.0050.006
Slightly volatile
Interest Debt Per Share0.30.440.1872
Slightly volatile
Debt To Assets0.140.110.0789
Slightly volatile
Days Of Payables Outstanding82.5778.6427.1412
Slightly volatile
Ebt Per Ebit0.91.491.0221
Slightly volatile
Quick Ratio3.023.1821.6653
Slightly volatile
Cash Ratio2.993.154.9076
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.171.151.0546
Slightly volatile
Fixed Asset Turnover0.02490.02620.1846
Slightly volatile
Debt Ratio0.140.110.0789
Slightly volatile
Price Sales Ratio451475911
Slightly volatile
Asset Turnover0.00250.00180.0024
Slightly volatile

Candel Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap259.8 M247.4 M209.9 M
Pretty Stable
Enterprise Value175.5 M167.2 M133.5 M
Pretty Stable

Candel Fundamental Market Drivers

Forward Price Earnings43.4783
Cash And Short Term Investments102.7 M

Candel Upcoming Events

4th of April 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Candel Therapeutics Financial Statements

Candel Therapeutics investors utilize fundamental indicators, such as revenue or net income, to predict how Candel Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue129.6 K123.1 K
Cost Of Revenue1.1 M1.1 M
Stock Based Compensation To Revenue 16.61  12.44 
Sales General And Administrative To Revenue 101.23  50.82 
Research And Ddevelopement To Revenue 149.67  82.12 
Capex To Revenue 9.34  7.62 
Revenue Per Share 0.00  0.01 
Ebit Per Revenue(319.44)(335.41)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Candel Therapeutics is a strong investment it is important to analyze Candel Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Candel Therapeutics' future performance. For an informed investment choice regarding Candel Stock, refer to the following important reports:
How To Invest In Candel
Details
Is Candel Stock a good investment?
Details
What is Candel Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Candel Therapeutics Correlation against competitors.
For more information on how to buy Candel Stock please use our How to buy in Candel Stock guide.
You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Candel Therapeutics. Projected growth potential of Candel fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Candel Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share
(0.56)
Revenue Per Share
0.001
Return On Assets
(0.43)
Return On Equity
(0.70)
Understanding Candel Therapeutics requires distinguishing between market price and book value, where the latter reflects Candel's accounting equity. The concept of intrinsic value—what Candel Therapeutics' is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Candel Therapeutics' price substantially above or below its fundamental value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
It's important to distinguish between Candel Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Candel Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Candel Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY